Stocks Health care JANX
NASDAQ · Health careJanux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. brought in $24M of revenue over the twelve months to June 30, 2026, up 5,367.0% from a year earlier. It posted a net loss of $102.6M. In fiscal 2025 capital spending exceeded operating cash flow by $83.3M. At June 30, 2026 it held $27.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Janux Therapeutics, Inc. does
Janux Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JANX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $10M | -$113.6M | -$1.83 | -$83.3M |
| 2024 | $10.6M | -$69M | -$1.28 | -$44.2M |
| 2023 | $8.1M | -$58.3M | -$1.32 | -$52.4M |
| 2022 | $8.6M | -$63.1M | -$1.52 | -$49.4M |
| 2021 | $3.6M | -$32.7M | -$1.39 | -$18.5M |
| 2021 | $0 | -$6.8M | -$7.41 | -$4.4M |
Latest SEC filings
What Janux Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- June 23, 2026Other event 8-K
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about JANX
What does Janux Therapeutics, Inc. do?
Janux Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JANX.
Is Janux Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $102.6M on revenue of $24M.
How much revenue does Janux Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Janux Therapeutics, Inc. reported revenue of $24M. That is 5,367.0% more than a year earlier.
When did Janux Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Follow JANX
Get an email when Janux Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow JANX: get an email when it filesWhere the numbers come from
Financial figures are the values Janux Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.